Expertise in
3
conditions

Veronika Ausch-Buxhofer

Ordensklinikum Linz Elisabethinen
Linz, AT 
Expertise in
3
conditions
Ordensklinikum Linz Elisabethinen
Linz, AT 
OverviewLocationsClinical Research

Overview

Veronika Ausch-Buxhofer practices in Linz, Austria. Ms. Ausch-Buxhofer is highly rated in 3 conditions, according to our data. Her top areas of expertise are Essential Thrombocythemia, Myelofibrosis, Blood Clots, Familial Colorectal Cancer, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 66 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Ordensklinikum Linz Elisabethinen
Linz, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)
A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: BeEAM, BEAM
Study Phase: Phase 2
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
Phase 1 Study to Evaluate the Feasibility and Efficacy of the Addition of P1101 (PEG-Proline-Interferon Alpha-2b) to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response (MR 4.5 or BCR-ABL Transcripts Not Detectable)
Phase 1 Study to Evaluate the Feasibility and Efficacy of the Addition of P1101 (PEG-Proline-Interferon Alpha-2b) to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response (MR 4.5 or BCR-ABL Transcripts Not Detectable)
Enrollment Status: Completed
Publish Date: January 04, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

66 Total Publications

Simultaneous auto-transplant and CD19 CAR T-cell 2nd line therapy followed by CD20 × CD3 bispecific antibody for refractory Burkitt lymphoma, a case report.
Simultaneous auto-transplant and CD19 CAR T-cell 2nd line therapy followed by CD20 × CD3 bispecific antibody for refractory Burkitt lymphoma, a case report.
Journal: Leukemia & lymphoma
Published: December 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ausch-Buxhofer's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile